In-stent restenosis stops here. RELINE with confidence.



AVAILABLE IN 7.5 cm LENGTH

The Continuing Evolution of a Revolutionary Device

GORE

VIABAHN® ENDOPROSTHESIS

HEPARIN BIOACTIVE SURFACE

PERFORMANCE through innovation

1996

Original GORE® HEMOBAHN® Endoprosthesis introduced in Europe

2002

Original device introduced in US as GORE® VIABAHN® Endoprosthesis

2003

TIP to HUB deployment introduced on 6–8 mm devices

2005

6–8 mm devices in US receive FDA approval for SFA indication

2007

GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface introduced in US

5–8 mm devices decreased in profile by one French size

2008

All device sizes receive FDA approval for iliac artery indication

2009

Laser technology enables the new contoured edge at proximal end

9–13 mm devices introduced with 0.035″ guidewire compatibility

2011

GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface 5–8 mm devices decreased in profile by one French size

2013

FDA approval for Revision of Arteriovenouse Access Grafts

25 cm Length: Longest stent-graft introduced in US

2014

5–7 mm devices receive FDA approval for treatment of in-stent restenosis in the SFA

Radiopaque markers on endoprosthesis introduced on 5–8 mm devices

2016

7.5 cm length introduced in US for 5–9 mm devices

Gore continues to evolve the GORE® VIABAHN® Endoprosthesis, demonstrating our commitment to providing our customers with innovative products.

Now with Radiopaque Markers for Enhanced Visibility

- Addition of four (4) gold radiopaque markers bonded to the graft at each end of endoprosthesis
- 5–8 mm diameter devices incorporate this change
- Delivery system and profile unchanged







The Longest Stent-Graft for Endoluminal Bypass

- 25 cm longest length available
- Covers more lesion with one device
- May reduce the need for overlapping devices

Total Endoluminal Bypass

Cover with Confidence
Covers and excludes the diseased irregular tissue of the arterial wall

ePTFE Lining
Provides barrier to in-stent restenosis

Nitinol Stent
Conformable yet durable

Heparin-Bonded Surface
Intended to provide sustained thromboresistance

Lowest Profile Stent-Graft
Reduced profile delivery system makes it even easier to reach and treat challenging SFA lesions



Individual Results May Vary

Contoured Proximal Edge

- Precision laser trimming technology enables manufacturing change
- Excess material at the proximal edge removed
- Contoured edge may improve flow dynamics at proximal end

Canine In Vivo IVUS Examples



Non-contoured edge



Contoured edge

Excess material removed at the device margin of the contoured edge compared to a non-contoured edge

Animal Acute Examples

Non-contoured edge



Contoured edge

Excess material removed at the device margin of the contoured edge compared to a non-contoured edge

CBAS® Heparin Surface

- Intended to provide a thromboresistant surface
- Sustained bioactivity*
- Proprietary end-point covalent bonding

GORE® VIABAHN® Endoprosthesis
with Heparin Bioactive Surface

The bioactive luminal surface of a 5 mm diameter GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface appears free of thrombus after two hours in an in vitro blood loop model.

Control Endoprosthesis

The non-bioactive luminal surface of a control endoprosthesis (5 mm diameter) appears covered with thrombus after 90 minutes in the same blood loop model (data on file).

Sustained Bioactivity



Long-term Heparin Activity of Explanted Heparin-bonded ePTFE Vascular Grafts in a Canine Model*

* Begovac PC, Thomson RC, Fisher JL, Hughson A, Gällhagen A. Improvements in GORE-TEX® Vascular Graft Performance by Carmeda® BioActive Surface Heparin Immobilization. *European Journal of Vascular and Endovascular Surgery* 2003;25(5):432-437.

Sizing Table

TIP to HUB Device Deployment — 0.014" or 0.018" Guidewire Compatibility (With radiopaque markers)

Device Sizing		Introducer Sheath (Fr)						
Endoprosthesis Labeled Diameter [1] (mm)	Recommended Vessel Diameter [2] (mm)	2.5 cm Device Length [1]	5 cm Device Length [1]	7.5 cm Device Length [1]	10 cm Device Length [1]	15 cm Device Length [1]	25 cm Device Length [1]	Recommended Balloon Diameter for Device Touch-up [3] (mm)
5	4.0–4.7	6	6	6	6	6	6	5
6	4.8–5.5	6	6	6	6	6	6	6
7	5.6–6.5	7	7	7	7	7	7	7
8	6.6–7.5	7	7	7	7	7	7[4]	8

TIP to HUB Device Deployment — 0.035" Guidewire Compatibility (Radiopaque markers on 5–8 mm devices)

Device Sizing		Introducer Sheath (Fr)						
Endoprosthesis Labeled Diameter [1] (mm)	Recommended Vessel Diameter [2] (mm)	2.5 cm Device Length [1]	5 cm Device Length [1]	7.5 cm Device Length [1]	10 cm Device Length [1]	15 cm Device Length [1]	25 cm Device Length [1]	Recommended Balloon Diameter for Device Touch-up [3] (mm)
5	4.0–4.7	7	7	7	7	7	7	5
6	4.8–5.5	7	7	7	7	7	7	6
7	5.6–6.5	8	8	8	8	8	8	7
8	6.6–7.5	8	8	8	8	8	8	8
9	7.6–8.5	–	9	9	9	9	–	9
10	8.6–9.5	11[4]	11[4]	–	11[4]	11[4]	–	10
11	9.6–10.5	11	11	–	11	–	–	12
13	10.6–12.0	12	12	–	12	–	–	14

1 Labeled device diameters and lengths are nominal.
2 Recommended endoprosthesis compression within the vessel is approximately 5–20%.
3 For the 11 and 13 mm diameter devices, balloon inflation pressure should not exceed 8 atm.
4 The 10 mm diameter device is compatible with the following 10 Fr introducer sheaths: CORDIS® AVANTI® Sheath Introducer, Boston Scientific SUPER SHEATH Introducer Sheath, B. Braun INTRADYN Tear-Away Introducer Sheath. The 8 mm x 25 cm device is not compatible with the 7 Fr COOK® CHECK-FLO® FLEXOR® Sheath.

GORE
Creative Technologies Worldwide

W. L. Gore & Associates, Inc.
Flagstaff, AZ 86004

+65.67332882 (Asia Pacific)
00800.6334.4673 (Europe)
800.437.8181 (United States)
928.779.2771 (United States)

goremedical.com

INTENDED USE / INDICATIONS: The GORE® VIABAHN® Endoprosthesis is indicated for improving blood flow in patients with symptomatic peripheral arterial disease in superficial femoral artery de novo and restenotic lesions up to 270 mm in length with reference vessel diameters ranging from 4.0 – 7.5 mm, in superficial femoral artery in-stent restenotic lesions up to 270 mm in length with reference vessel diameters ranging from 4.0 – 6.5 mm, and in iliac artery lesions up to 80 mm in length with reference vessel diameters ranging from 4.0 – 12 mm. The GORE® VIABAHN® Endoprosthesis is also indicated for the treatment of stenosis or thrombotic occlusion at the venous anastomosis of synthetic arteriovenous (AV) access grafts. Refer to Instructions for Use at goremedical.com for a complete description of all contraindications, warnings, precautions and adverse events. ℞ Only

Products listed may not be available in all markets.